



Contact: Julie Bryant  
VP Business Development and Marketing  
GeneGo, Inc.  
(858) 756 7996  
julie@genego.com

## **SIENABIOTECH SPA LICENSES METACORE™ FROM GENEGO**

**St. Joseph, Michigan, July 6th, 2005** – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Sienabiotec SpA has licensed MetaCore version 2.5, GeneGo’s platform for mining and visualization of high-throughput experimental data in the context of biological networks, pathways and diseases. MetaCore enables concurrent visualization and analysis of gene expression, proteomics and metabolomics data in multiple formats including LocusLink, Genbank, RefSeq, All Affymetrix arrays tags, OMIM, Unigene, SwissProt as well as other approved gene symbol IDs. MetaCore’s content is manually assembled from full text experimental articles by qualified curators. The latest release, MetaCore version 2.5, features multiple functions for statistical analysis of biological networks, inter-experimental comparisons, and new algorithms for pathways prioritization based on tissue specificity, sub-cellular localization, interaction types, and relevance to cellular processes.

“We tested several platforms in the systems biology marketplace and felt that MetaCore best suited our current needs,” said Dr. Georg C. Terstappen, Vice President Discovery Research at Sienabiotec SpA. “We felt that the content was broad, deep with a high level of quality control and we can access information without having experimental data as a starting point,” included Dr. Andreas Kremer, Head of Bioinformatics.

“We are happy to welcome Sienabiotec SpA as the first Italian company on our rapidly growing list of new customers”, said Julie Bryant VP of Business Development. “With fast evolution of OMICs technologies, and concurrent analysis and cross-validation of multiple data types becoming increasingly important, we emphasize such features in the new version of MetaCore. Sienabiotec SpA will be able to visualize and directly compare gene expression and proteomic data on the same networks and pathways maps. Our new version features over 400 static maps of canonical signaling and metabolic pathways and eight network building algorithms.”

### **About GeneGo**

GeneGo develops systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, siRNA and other

phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 2.5, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug<sup>TM</sup> is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase<sup>TM</sup> represents the knowledge base for MetaCore. For more information, please visit the company's web site at [www.genego.com](http://www.genego.com).

MetaCore<sup>TM</sup>, MetaBase<sup>TM</sup> and MetaDrug<sup>TM</sup> are trademarks of GeneGo, Inc.